{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:35:55Z","timestamp":1790516155168,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.clml.2021.02.005","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T11:29:48Z","timestamp":1615116588000},"page":"427-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Inhibitor of BRAFV600E Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-8868","authenticated-orcid":false,"given":"Svetlana Yu.","family":"Smirnova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyubov S.","family":"Al-Radi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana N.","family":"Moiseeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-977X","authenticated-orcid":false,"given":"Eduard G.","family":"Gemdzhian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor A.","family":"Yakutik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-7531","authenticated-orcid":false,"given":"Hunan L.","family":"Julhakyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav A.","family":"Novikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady M.","family":"Galstyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-9187","authenticated-orcid":false,"given":"Andrey B.","family":"Sudarikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.02.005_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.02.005_bib2","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.V80.9.2203.2203","article-title":"A\u00a0single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia","volume":"80","author":"Tallman","year":"1992","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2021.02.005_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/10428194.2011.565097","article-title":"Purine analog toxicity in patients with hairy cell leukemia","volume":"52","author":"Tadmor","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.02.005_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-020-1325-9","article-title":"Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis","volume":"15","author":"Epperla","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clml.2021.02.005_bib5","first-page":"1056","article-title":"Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy","volume":"52","author":"Vedantham","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2021.02.005_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12254-016-0269-1","article-title":"Long-term treatment of hairy cell leukemia with interferon-\u03b1: still a viable therapeutic option","volume":"9","author":"Bohn","year":"2016","journal-title":"Memo"},{"key":"10.1016\/j.clml.2021.02.005_bib7","first-page":"111","article-title":"[Aspects of the course and treatment of hairy cell leukemia]","volume":"2","author":"Al-Radi","year":"2009","journal-title":"Clin Oncohematol"},{"key":"10.1016\/j.clml.2021.02.005_bib8","first-page":"127","article-title":"Past and present role of interferon in hairy cell leukemia","volume":"Vol 5","author":"Thompson","year":"2000"},{"issue":"suppl 2","key":"10.1016\/j.clml.2021.02.005_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/10428194.2011.570819","article-title":"Infectious complications in hairy cell leukemia","volume":"52","author":"Kraut","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.02.005_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0609.2009.01259.x","article-title":"Risk factors for severe infections in patients with hairy cell leukemia: a long-term study of patients","volume":"83","author":"Damaj","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.02.005_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-med-090514-030732","article-title":"B-Raf inhibition in the clinic: present and future","volume":"67","author":"Fiskus","year":"2016","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clml.2021.02.005_bib12","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3109\/10428194.2014.1001988","article-title":"Novel therapeutic options for relapsed hairy cell leukemia","volume":"56","author":"Jain","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.02.005_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/14740330903427951","article-title":"Inherent and iatrogenic immune defects in hairy cell leukemia: revisited","volume":"9","author":"Dasanu","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clml.2021.02.005_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ajh.2830160410","article-title":"Infectious complications in 127 patients with hairy cell leukemia","volume":"16","author":"Golomb","year":"1984","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.02.005_bib15","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2021.02.005_bib16","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMc1202124","article-title":"BRAF inhibition in refractory hairy-cell leukemia","volume":"366","author":"Dietrich","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2021.02.005_bib17","doi-asserted-by":"crossref","first-page":"106315","DOI":"10.1016\/j.leukres.2020.106315","article-title":"Disseminated, yet dissembled: rare infections behind the veil of classical hairy cell leukemia","volume":"90","author":"Shallis","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.02.005_bib18","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00277-013-1987-7","article-title":"Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis","volume":"93","author":"Maurer","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.02.005_bib19","doi-asserted-by":"crossref","first-page":"E180","DOI":"10.1002\/ajh.25474","article-title":"Low-dose vemurafenib in hairy cell leukemia patients with active infection","volume":"94","author":"Bohn","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.02.005_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/bloodadvances.2018027466","article-title":"Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib","volume":"3","author":"Shenoi","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.02.005_bib21","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1200\/JCO.2012.45.9495","article-title":"Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia","volume":"31","author":"Dietrich","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.02.005_bib22","first-page":"51","article-title":"[The place of splenectomy in the treatment of acute respiratory failure in the patient with hairy cell leukemia]","volume":"62","author":"Galstyan","year":"2017","journal-title":"Russian J Hematol Transfusiol"},{"key":"10.1016\/j.clml.2021.02.005_bib23","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.2012.082404","article-title":"Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation","volume":"98","author":"Peyrade","year":"2013","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:56Z","timestamp":1761871016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2152265021000665"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.02.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitor of BRAFV600E Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}